跳至主要内容
临床试验/NCT02062879
NCT02062879终止3 期

Ketamine Patient-Controlled Analgesia for Acute Pain in Native Airway Multiple and Orthopedic Trauma Patients: A Randomized, Active Comparator, Blinded Trial

University of Cincinnati1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2014年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
20
试验地点
1
主要终点
Total Daily Opioid Requirement

研究概览

简要总结

This study will compare ketamine and hydromorphone as alternative patient-controlled interventions for trauma-related pain. Patients receiving ketamine PCA are expected to require less total and breakthrough opioid and to have similar or improved objective pain scores. Patients receiving ketamine are also expected to have shorter duration of supplemental oxygen requirement, fewer episodes of oxygen desaturation, improved pulmonary toilet, lower use of antiemetics, and shorter times to first bowel movement. Ketamine is further expected to be associated with decreased intensive care unit and hospital lengths of stay, faster time to maximum allowable ambulation, decreased opioid dosage at discharge, and lower report of chronic pain syndromes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age greater than or equal to 18 years
  • Total Injury Severity Score greater than 9
  • Functioning intravenous catheter present per standard of care
  • Patient planned to receive PCA for acute pain per standard of care
  • Patient ability to effectively use a PCA device as assessed by the primary attending trauma service
  • Negative pregnancy test for women of childbearing age

排除标准

  • Body mass index greater than 35
  • History of active psychiatric disease
  • Acute or chronic liver or renal failure
  • History of heart failure or coronary artery disease
  • Patients with documented chronic pain syndrome who use opioids as maintenance medication in outpatient therapy
  • Patients who abuse alcohol and are at high risk for alcohol withdrawal
  • Intubated patients
  • Glasgow Coma Scale score less than 13, or motor subscore less than 6
  • Documented allergy to ketamine, hydromorphone, or lorazepam
  • Pregnancy
  • Incarceration

研究组 & 干预措施

Ketamine

Experimental

Ketamine 90mg/30 mL PCA (3 mg/mL)

干预措施: Ketamine (Drug)

Hydromorphone

Active Comparator

Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)

干预措施: Hydromorphone (Drug)

结局指标

主要结局

Total Daily Opioid Requirement

时间窗: Participants will be followed for their entire hospital stay, an expected average of 1 week.

Daily breakthrough opioid requirement plus non-breakthrough opioid use in milligrams of morphine equivalents

次要结局

  • Breakthrough Daily Opioid Requirement(Participants will be followed for their entire hospital stay, an expected average of 1 week)
  • Median Pain Score(Participants will be followed for their entire hospital stay, an expected average of 1 week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sheila Takieddine

Policy Development Specialist

University of Cincinnati

研究点 (1)

Loading locations...

相似试验